Please login to the form below

Not currently logged in
Email:
Password:

Immunomedics

This page shows the latest Immunomedics news and features for those working in and with pharma, biotech and healthcare.

Bluebird and Celgene BCMA CAR-T kicks off ASCO

Bluebird and Celgene BCMA CAR-T kicks off ASCO

Immunomedics will present phase I/II result of its Trop-2-targeting sacituzumab govitecan (IMMU-132) in breast cancer - which prompted an investor revolt when the biotech’s former management tried

Latest news

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Collaboration, licence. 310. Immunomedics/ Royalty Pharma. Royalty rights to sacituzumab govitecan (IMMU- 132) across all indications. ... The whole episode resulted in the resignation of the Immunomedics CEO and CSO.

  • Deal Watch March 2017 Deal Watch March 2017

    In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... The activist investor venBio, which has recently gained

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.

  • Pharma deals during October 2013 Pharma deals during October 2013

    The dispute between the parties concerns development delays that Immunomedics argued were material breach of the agreement. ... On termination, all rights revert back to Immunomedics and it is expected that arbitration will continue in parallel with

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics